Quick Answer
Spyre Therapeutics, Inc. reported Total Assets of $777.78 million for the year ending 2025.
- Spyre Therapeutics, Inc. showed an increase of +27.8% in Total Assets from 2024 to 2025.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2016: $35.54 million | Q2 2016: $77.30 million | Q3 2016: $72.06 million | Q1 2017: $61.27 million | Q2 2017: $67.14 million | Q3 2017: $60.50 million | Q1 2018: $49.79 million | Q2 2018: $79.71 million | Q3 2018: $71.28 million | Q1 2019: $128.52 million | Q2 2019: $117.49 million | Q3 2019: $100.10 million | Q1 2020: $64.78 million | Q2 2020: $172.91 million | Q3 2020: $155.63 million | Q1 2021: $163.61 million | Q2 2021: $146.98 million | Q3 2021: $129.06 million | Q1 2022: $83.17 million | Q2 2022: $106.71 million | Q3 2022: $91.57 million | Q1 2023: $52.45 million | Q2 2023: $243.53 million | Q3 2023: $207.27 million | Q1 2024: $487.60 million | Q2 2024: $436.07 million | Q3 2024: $421.09 million | Q1 2025: $569.78 million | Q2 2025: $538.83 million | Q3 2025: $504.60 million.
- Over the full 11 years of available data (2015 to 2025), Spyre Therapeutics, Inc.'s Total Assets has grown by 1,912.2%.
- Historical annual values: Fiscal year 2025: $777.78 million | Fiscal year 2024: $608.48 million | Fiscal year 2023: $341.86 million | Fiscal year 2022: $71.14 million | Fiscal year 2021: $109.93 million | Fiscal year 2020: $161.62 million | Fiscal year 2019: $83.18 million | Fiscal year 2018: $77.74 million | Fiscal year 2017: $56.08 million | Fiscal year 2016: $67.06 million | Fiscal year 2015: $38.65 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: